Maximum Dose of Ingrezza (Valbenazine)
The maximum recommended daily dose of Ingrezza (valbenazine) is 80 mg once daily for both tardive dyskinesia and chorea associated with Huntington's disease. 1
Standard Dosing
According to the FDA prescribing information, the dosing algorithm is straightforward:
For Tardive Dyskinesia:
- Initial dose: 40 mg once daily
- After 1 week: Increase to the recommended dose of 80 mg once daily
- Alternative doses: 40 mg or 60 mg once daily may be considered based on response and tolerability 1
For Chorea Associated with Huntington's Disease:
- Initial dose: 40 mg once daily
- Titration: Increase by 20 mg increments every 2 weeks
- Target dose: 80 mg once daily
- Alternative doses: 40 mg or 60 mg once daily may be considered based on response and tolerability 1
Dose Reductions Required in Specific Populations
The maximum dose must be reduced to 40 mg once daily in the following situations:
- Moderate or severe hepatic impairment (Child-Pugh score 7-15) 1
- Known CYP2D6 poor metabolizers 1
- Concomitant use with strong CYP3A4 inhibitors 1
- Concomitant use with strong CYP2D6 inhibitors 1
Clinical Evidence Supporting the 80 mg Maximum
The 80 mg dose demonstrated superior efficacy in pivotal trials. For tardive dyskinesia, the 80 mg dose showed a placebo-subtracted difference of -3.1 points on the AIMS dyskinesia total score, which was statistically significant, while the 40 mg dose showed -1.8 points 1. In Huntington's disease chorea, over 80% of patients were taking the 80 mg dose by the end of the 12-week treatment period 1.
Importantly, efficacy appears to plateau at 80 mg once daily, with minimal additional benefit expected beyond this dosage 2. This pharmacokinetic and exposure-response modeling supports 80 mg as both the maximum effective and maximum recommended dose.
Critical Safety Consideration
Do not use strong CYP3A4 inducers concomitantly with valbenazine, as this combination is not recommended 1. This differs from the dose reduction strategy used with inhibitors.
The 60 mg dose, while not studied in initial trials, was approved based on model-informed drug development showing predicted efficacy within the range of the studied 40 mg and 80 mg doses 3.